well incremental and XXX QX, afternoon, team thank quarter Revenue in call. the of the as of by quarter end $X.XX The improved steady and above $XXX revenue of is Good guidance. XX.X% reflecting solid high of on to of billion better-than-expected deliver, today's remain margin results, basis actions executed savings share sequentially joining you earnings. we of year.
Earnings start the an last points million Parmeet. X.X%, we improvement the Operating end per for $X.XX the and improvement market. posted and annualized deliver third $X.XXX of announced declined fiscal to Agilent delivering everyone, in the Thanks, the from the track
of at are our As both in the guidance QX revenue continue a are EPS, we our result our opportunities growth and our we referenced midpoint promising call. raising for strong make and that to QX in performance, investments most
announce digital organization customer our are enhance expansion experience value driving ecosystem, and mobilizing increasing differentiated growth talk our margin strategic focus creation transformation moment. we ecosystem the execution further We're to I'll acquisitions that were and our excited which X our in initiatives, biopharma quarter, a investing we capabilities. our and plus, Separately digital the to in in about to on demonstrate accelerate through
you know of change faster As is than ever. well, pace the
front of of still, so markets, and add not to in on capitalize we Our competitors standing and neither can and us. We're we. customers execution, pace accelerating our are opportunities innovation are
forward. should I We listen to growth the meet their are Advanced and key Agilent connect on sharply to and move including focused perspectives employees, around globe and Materials. strengths continue on how PFAS shareholders biopharma, on customers vectors, with we our and to build
customer to shareholders. vital marketplace Agilent to and even on in even The future, and to win team more and nimble entire the clear add focused customers to more company's is becoming the value continue what is
on December you'll planned excited for at our about announce Day Investor transformation York long-term strategy, have growth. to adapting market evolving and trends greatest that are hear our accelerating while and our XX. an quickly area of we to changes pace these innovation, our We're more We of topics in New return
further let's smallest, our than our ended QX our quarter the All about markets better Now academia expected. government, except talk is which end results. and
single than seeing pharma, And in better market better continues largest small high Our our relatively digits, declined to slightly performance pressured, be molecules. expectations. while we are biopharma
providing strong market. performance show solutions in continued workflow small the exceeded PFAS for environmental. continued led pharma Europe leadership as Geographically, molecule Our in to environmental strength well expectations as by in
other with line regions Our performed roughly expectations. in
to instrument unit, Sciences digits. $XXX While million constrained, Applied budgets equipment activity in When in across Markets constrained, environmental and all our with saw X%, growing performance book-to-bill while plus most it Group mid-single down regions and was remains looking the remain in business than the business encouraging greater QX, low lab at The capital was continue end growth and forensics. consumables single-digit side the we again that Life group see services X. decline instrument with our reported of revenue, a good by markets
that much The to digits. mid-single bright Consumers delivering helps goals by their continue reach the be team while a up less other smaller of the introduction using growing a and answers LSAG footprint. power GC GCs to busy by innovating spot, customers efficiently XXXX was has XX% sustainability with also than
total of record XX% in year-on-year, business the Once growth, versus capital quarter. service the of showed growth and double-digit China, quarter, the continues the meaningful revenue we strength the million quarter business. constrained region represented revenue digits. mid-single Moving CrossLab but of we of despite last the resiliency $XXX Group, on up again, for where the ACG margin solid that contracts every grew except drove to Agilent business operating demonstrating another beyond improvement revenue environment. were XX%, of delivered And equipment nearly recurring down in also delivered modestly ACG which a
Genomics grew by an Group representing and but testament digits genomics. analysis, customers strength our we $XXX posted decline, on value productivity cell NASD and their The rates reached the instruments. a declines ally the our in was And Diagnostics million our them of goals. X% and ongoing mid-single strategy net to revenue, our offset business providing continued having of are to is The increasing in and
on team has as revenues remained QX step and are in CapEx the sequentially them. NASD's deeper putting to Agilent we the face constrained sequentially track first QX. a down relationships consistent and in in fostering of environment, up our customers with for In expected, stepped NASD
We and opportunities. disciplined continue to high-growth while investing in be execute well
The As speak I high on expanding and the biopharma for drug ecosystem antibody modalities were a our a rapidly agreement July, Canada-based to ingredients. focus we mentioned adds and contract manufacturing microbial leading services. therapeutics announce active revenue, acquisitions of digital fermentation, pharmaceutical oligonucleotides strengthening to capabilities organization. to X growing by builds CRISPR customers. increasing on BIOVECTRA late well In Agilent earlier, specialized definitive in company on acquire development that recurring potency and we signed conjugates thrilled as as BIOVECTRA, and portfolio Agilent
enables acquisition calendar us deliver It that The also gene during year customers company looking team combined revenue with when world-class revenue The year. editing on forward be BIOVECTRA complete the by growth brings more than to delivered XXXX double-digit welcoming to expect this closed to of in to Agilent. and BIOVECTRA and solution. the end NASD a remains the $XXX track capabilities year, million we're the
Sigsense CrossLab their improve suite applications the of that Sigsense, Technology power of also digital to the team our already customers and lab Connect, through customers of already acquisition optimize Agilent. A part that performance. Sigsense artificial operations. is who to lab of startup uses announced to At hearty a the monitoring available is we intelligence a California help based the welcome end quarter,
revenue, Green the My quarter, sustainability showcases to portfolio Lab certified large growing the products we XX% Instruments and with ACT our our customers a ESG their products released now continue the GC which with that benefits. for During regularly annual release new like we XXXX goals. and label accounts environmental instrument report, all help of of reach
of Magazine's the we the world. XXX most top that ranked XX proud also Time in sustainable recently are We in have companies
After the Bob well our the our be provide Bob comments, now of the to remarks. will Bob. I will results on back Over details for delivers closing his for as remainder outlook some you, year. as
